SCYNEXIS, Inc.
SCYNEXIS, Inc.
Your view on SCYX
Overview
What the company does, where it operates, and who runs it.
About SCYNEXIS, Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- David Gonzalez Angulo
- Headquarters
- 1 Evertrust Plaza, Jersey City, NJ, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- David Gonzalez Angulo
- Headquarters
- 1 Evertrust Plaza, Jersey City, NJ, US
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC).
The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC).
It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp.
The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for SCYNEXIS, Inc., and the rating behind it. SCYX last traded at $3.81; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for SCYNEXIS, Inc.. Starting points for SCYNEXIS, Inc.: EPS -$0.87, beta 1.06 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for SCYNEXIS, Inc.. SCYNEXIS, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for SCYNEXIS, Inc.. Trailing twelve-month EPS for SCYNEXIS, Inc. stands at -$0.87. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for SCYNEXIS, Inc.. SCYNEXIS, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
SCYNEXIS, Inc. valued side by side against its closest peers. SCYNEXIS, Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold SCYNEXIS, Inc., and how their positions are changing. At a $24.0M market value, institutional positions materially move SCYNEXIS, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by SCYNEXIS, Inc. executives and directors. Shares of SCYNEXIS, Inc. have traded between $0.56 and $1.49 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming SCYNEXIS, Inc.. SCYNEXIS, Inc. is a $24.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming SCYNEXIS, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for SCYNEXIS, Inc.. Coverage tracks SCYNEXIS, Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.